Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

McGill University

$150,000.00

Assessment of Soluble Prorenin Receptor as a Prostate Cancer Biomarker

EF 2013-14

Résumé
Prostate cancer (PC) is one of the most common types of cancer among men. Although only 1 in 24 PC patients die from the disease, PC is the second leading cancer-related cause of death among men. The number of people that die from PC is relatively high because many men get PC and some of the cases are metastatic and dangerous. In order to decrease the mortality resulting from PC, powerful screening tools have to be in place to detect the critical situations of PC and treat them accordingly. Currently, clinicians rely solely on one biomarker called the prostate-specific antigen (PSA) to screen and assess the progress of PC in men. Ideally, the level of PSA should correlate with the presence and progress of the disease. Nonetheless, PSA is not an ideal biomarker because the level of PSA in the blood can be independent of the presence or stage of PC. For this reason, the discovery of alternative PC biomarkers that are more reliable than PSA is crucial. In this study, we hypothesize that one protein, which elevates after eliminating an anti-cancer protein, to be more reliable than PSA in screening for PC. I will utilize numerous tumor and serum samples collected from PC patients and animal models to evaluate the ability of this protein to detect PC.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
299876
Name
Mohammad Amro H
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Assessment of Soluble Prorenin Receptor as a Prostate Cancer Biomarker
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Angiogenesis; Enzyme-Linked Immunosorbent Assay (Elisa); Mtor-Signaling; Prorenin Receptor; Prostate Cancer; Soluble Prorenin Receptor; Tumor Growth; Tumor Microarrays (Tma); Tumor Suppressor Gene; Vacuolar Atpase Activity
Abstract
Prostate cancer (PC) is one of the most common types of cancer among men. Although only 1 in 24 PC patients die from the disease, PC is the second leading cancer-related cause of death among men. The number of people that die from PC is relatively high because many men get PC and some of the cases are metastatic and dangerous. In order to decrease the mortality resulting from PC, powerful screening tools have to be in place to detect the critical situations of PC and treat them accordingly. Currently, clinicians rely solely on one biomarker called the prostate-specific antigen (PSA) to screen and assess the progress of PC in men. Ideally, the level of PSA should correlate with the presence and progress of the disease. Nonetheless, PSA is not an ideal biomarker because the level of PSA in the blood can be independent of the presence or stage of PC. For this reason, the discovery of alternative PC biomarkers that are more reliable than PSA is crucial. In this study, we hypothesize that one protein, which elevates after eliminating an anti-cancer protein, to be more reliable than PSA in screening for PC. I will utilize numerous tumor and serum samples collected from PC patients and animal models to evaluate the ability of this protein to detect PC.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Mohammad, Amro H
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~